Serum Institute of India (SII) and US-based Novavax, Inc. have received emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant by the Drugs Controller General of India (DCGI).

The vaccine will be manufactured and marketed in India by SII under the brand name COVOVAX™.

Sharing his views, Adar Poonawalla, Chief Executive Officer, Serum Institute of India (SII), said, “The approval of COVOVAX by DCGI is a significant milestone in strengthening our immunization efforts across India and LMICs. We are certain that as the repertoire of the COVID-19 vaccine increases, we will be poised strongly to save the lives of millions of people against the pandemic.”

“We expect the authorization of our vaccine to serve a vital need in India, helping to increase the vaccination rate in a country where a significant number of doses is needed to control the pandemic,” said Stanley C. Erck, President and Chief Executive Officer, Novavax.  

The Novavax/SII vaccine recently received Emergency Use Listing (EUL) with the World Health Organization (WHO), EUA in Indonesia and the Philippines.